International Vaccine Institute strategic demand forecasting; and Sabin – communications and advocacy. Besides leading the consortium, IVI generated evidence for decision-making such as disease burden, country vaccine introduction cases and a global investment case. From 2010 to 2016, DVI operated in Brazil, Burkina Faso, Cambodia, Colombia, Gabon, India, Kenya, Thailand, and Vietnam. From 2013-2015, with funding from Germany’s Federal Ministry of Education & Research (BMBF), IVI continued support for preclinical development of dengue vaccines by Brazil’s Butantan Institute and Vietnam’s VaBiotech. After the 2016 licensure of Sanofi Pasteur’s Dengvaxia vaccine, the DVI project came to a close and its IVI staff transitioned to
Oswaldo Cruz Foundation Rio de Janeiro and other locations; however, it contributes to improving health throughout the country, through its support to the Sistema Único de Saúde (Unified Health System, the Brazilian public health system), its proposals on public health policy-making, its research activities, its scientific expeditions, and the reach of its health services and products. Fiocruz is one of the founding members of the International Association of National Public Health Institutes, a membership organization of national public health institutes. Oswaldo Cruz Foundation The Oswaldo Cruz Foundation (Portuguese Fundação Oswaldo Cruz, also known as FIOCRUZ) is a scientific institution for research and development